Ironwood Pharmaceuticals Company Profile (NASDAQ:IRWD)

Analyst Ratings

Consensus Ratings for Ironwood Pharmaceuticals (NASDAQ:IRWD) (?)
Ratings Breakdown: 5 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $14.50 (1.61% upside)

Analysts' Ratings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Show:
DateFirmActionRatingPrice TargetActions
7/21/2016WedbushReiterated RatingNeutral$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2016MizuhoBoost Price TargetBuy$16.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016JP Morgan CazenoveReiterated RatingOverweight$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2016Wood & CompanyInitiated CoveragePositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2016Goldman Sachs Group Inc.Initiated CoverageNeutral$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/20/2016BTIG ResearchReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Leerink SwannReiterated RatingHold$12.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Barclays PLCLower Price TargetEqual Weight$15.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015JPMorgan Chase & Co.Lower Price TargetOverweight$23.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/1/2015Cantor FitzgeraldReiterated RatingHold$13.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015Bank of America Corp.Initiated CoverageBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/13/2015WallachBeth CapitalBoost Price TargetHold$15.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/9/2016Q116($0.14)($0.08)$52.97 million$66.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2016Q415($0.17)($0.10)$44.78 million$53.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.20)($0.25)$39.81 million$39.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.22)($0.34)$36.08 million$27.74 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.23)($0.24)$32.30 million$28.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414($0.21)($0.27)$35.20 million$38.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.32)($0.30)$21.20 million$16.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q214($0.36)($0.38)$15.75 million$6.84 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2014Q1($0.44)($0.38)$8.52 million$14.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/21/2014Q413($0.50)($0.43)$7.13 million$5.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2013Q313($0.57)($0.51)$6.54 million$4.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2013Q2 2013($0.70)($0.57)$6.32 million$9.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2013Q1 2013($0.71)($0.87)$8.94 million$3.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/15/2013Q4 2012($0.49)($0.41)$16.17 million$27.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/16/2012$0.17$0.42ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/17/2012($0.31)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2012($0.23)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2012($0.11)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2011($0.20)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2011($0.18)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2011($0.17)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.16)($0.08)($0.11)
Q2 20162($0.13)($0.12)($0.13)
Q3 20162($0.17)($0.16)($0.17)
Q4 20162($0.20)($0.16)($0.18)
Q1 20171($0.15)($0.15)($0.15)
Q2 20171($0.09)($0.09)($0.09)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.04$0.04$0.04
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/3/2016Lawrence S OlanoffDirectorSell2,200$12.92$28,424.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Halley E GilbertInsiderSell20,275$12.19$247,152.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Peter M HechtCEOSell120,000$10.72$1,286,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Lawrence S OlanoffDirectorSell2,200$11.11$24,442.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2016Edward P OwensDirectorBuy10,000$8.32$83,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2016Gina ConsylmanCAOSell420$8.50$3,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2016Mark G CurrieInsiderSell152,154$8.53$1,297,873.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2016Thomas GraneyCFOSell563$8.50$4,785.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Peter M. HechtCEOSell73,418$11.07$812,737.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Lawrence S OlanoffDirectorSell2,200$11.77$25,894.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Lawrence S OlanoffDirectorSell3,725$10.97$40,863.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Peter M HechtCEOSell200,000$15.62$3,124,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2015Joseph C Cook JrDirectorSell5,883$15.54$91,421.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Bryan E RobertsDirectorSell95,998$15.20$1,459,169.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2015Peter M HechtCEOSell63,442$15.75$999,211.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Joseph C Cook JrDirectorSell35,500$15.60$553,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Bryan E RobertsDirectorSell19,792$15.20$300,838.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2014Bryan E RobertsDirectorSell200,000$14.24$2,848,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Michael J HigginsCOOSell50,000$14.56$728,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Mark CurrieInsiderSell25,000$13.93$348,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2014Mark CurrieInsiderSell25,000$11.67$291,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2014Mark CurrieInsiderSell20,000$14.38$287,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Bryan RobertsDirectorSell21,200$12.57$266,484.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Bryan RobertsDirectorSell823,350$12.71$10,464,778.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2014Bryan RobertsDirectorSell55,450$12.01$665,954.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Terrance McguireDirectorSell2,083$9.11$18,976.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Michael J HigginsCOOSell150,000$11.74$1,761,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2013Thomas A MccourtInsiderSell40,000$17.00$680,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2012Peter M HechtCEOBuy50,000$11.65$582,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2012Fmr LlcInsiderSell19,305$13.02$251,351.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateHeadline
07/23/16 08:41 AMIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/23/16 08:41 AMIronwood Pharmaceuticals Inc. (IRWD) Hits New 52-week High During July 21 Session - Equities.com
07/21/16 04:52 PMRecent Analysts Rating Overview: Eli Lilly and Company (NYSE:LLY) , Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Street Updates
07/21/16 03:01 PMIronwood Pharmaceuticals to Host Second Quarter 2016 Investor Update Call - [Business Wire] - Ironwood Pharmaceuticals, Inc. today announced it will host its second quarter 2016 investor update conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 4, 2016.
07/20/16 02:43 PMShares Positive Over the Past Month: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - TGP
07/20/16 07:42 AMIronwood Pharmaceuticals Inc. (IRWD) Hits New 52-week High During July 18 Session - Equities.com
07/20/16 07:42 AMEquity Roundup: Stock Performance Focus on Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Press Telegraph
07/19/16 04:47 PMIronwood Pharmaceuticals Inc. (IRWD) Broke Out To A New High For The Year
07/18/16 04:52 PMShares of Ironwood Pharmaceuticals (IRWD) Rally 1.8% - TheFounders Daily
07/16/16 04:25 PMWill Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Surprise Analysts? - Investor Newswire
07/16/16 08:03 AMShares Experiencing a Downtrend: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - TGP
07/16/16 08:03 AMPerformance report of the company: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - News Oracle
07/16/16 08:03 AMIronwood Pharmaceuticals Inc. (IRWD) Jumps 8.45% on July 15 - Equities.com
07/15/16 03:44 PMIncreased Volatility Noted on Shares of: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Engelwood Daily
07/15/16 08:29 AMIronwood Pharmaceuticals Class A (NASDAQ:IRWD) Short Interest Decreased By 4.36% - Consumer Eagle
07/15/16 08:29 AMIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 04:53 PMIronwood Pharmaceuticals Inc. (IRWD) is Trading Lower on Unusual Volume for July 12 - Equities.com
07/13/16 07:36 AMShort Term Rating on Ironwood Pharmaceuticals (IRWD) - Trade Calls
07/12/16 09:03 AMStock on the Rise for the Quarter: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Engelwood Daily
07/12/16 09:03 AMIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 09:03 AMIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Updated Price Targets - FTSE News
07/12/16 09:03 AMHave a look at Analyst Actions: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) , Endologix, Inc. (NASDAQ:ELGX) - Street Updates
07/12/16 08:28 AMCoverage Initiated on Select Generic Drugs Makers Equities -
07/09/16 08:04 AMBvf INC Decreased Stake in Ironwood Pharmaceuticals INC (NASDAQ:IRWD) by $11.80 Million as Shares Declined - Press Telegraph
07/09/16 08:04 AMIronwood Pharmaceuticals Inc. (IRWD) Hits New 52-week High During July 07 Session - Equities.com
07/07/16 07:35 AMInsiders are Gradually Selling Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Telanagana Press
07/07/16 07:35 AM1.24 is Ironwood Pharmaceuticals Inc's (NASDAQ:IRWD) Institutional Investor Sentiment - Engelwood Daily
07/07/16 07:35 AMBroker Outlook For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Fiscal Standard
07/02/16 07:37 AMEcor1 Capital LLC Increased Ironwood Pharmaceuticals INC (NASDAQ:IRWD) by $12.40 Million as Shares Declined - Press Telegraph
07/01/16 07:29 AMIronwood Pharmaceuticals Class A (NASDAQ:IRWD) Sellers Covered 4.36% of Their Shorts - Engelwood Daily
07/01/16 07:29 AMRecently Issued Stock Ratings For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Fiscal Standard
06/30/16 07:33 AMAnalyst Rating Update on Ironwood Pharmaceuticals (IRWD) - TheFounders Daily
06/29/16 07:31 AMIronwood Pharmaceuticals, Inc. Stock Is Rising Now - Press Telegraph
06/29/16 07:31 AMAre Analysts Bearish Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) After Last Week? - Press Telegraph
06/25/16 08:32 AMStock Tracing Lower on the Week Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Engelwood Daily
06/24/16 07:18 AMIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Earnings Glance and Target Price Review - Engelwood Daily
06/22/16 04:48 PMIronwood Pharmaceuticals (NASDAQ:IRWD) Analyst Rating Consensus - TheFounders Daily
06/21/16 04:23 PMFirst Week of February 2017 Options Trading For Ironwood Pharmaceuticals (IRWD) - Money Morning
06/17/16 07:28 AMTwo Buzzers within Traders Radar: Quest Diagnostics Incorporated (NYSE:DGX) , Ironwood Pharmaceuticals, Inc ... - Street Updates
06/15/16 04:43 PMEarnings Report: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), Sunrun Inc. (NASDAQ:RUN) - Beacon Chronicle
06/15/16 09:22 AMCurrent Update on Price Fluctuations: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) , DexCom, Inc. (NASDAQ:DXCM) - Street Updates
06/14/16 04:34 PMNew Market Research Report: Ironwood Pharmaceuticals, Inc. (IRWD) - Financial and Strategic SWOT Analysis Review
06/14/16 09:31 AMIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) And Big Pharma Partners Set To Gain on Linzess sNDA - Market Exclusive
06/13/16 04:24 PMIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) And Big Pharma Partners Set To Gain on Linzess sNDA
06/10/16 10:31 AMIronwood/Allergan's Linzess sNDA Accepted for FDA Review -
06/10/16 07:30 AMPacira Pharmaceuticals : Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
06/10/16 07:30 AMWhich way Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earnings may go
06/09/16 02:19 PMHere's Why Ironwood Pharmaceuticals, Inc. Jumped 19.52% in May - A first-quarter earnings report packed with good news, and a well-received investor presentation, caused shares to move higher in May.
06/09/16 07:23 AMAllergan (AGN), Ironwood Pharma's (IRWD) Linaclotide sNDA Accepted for Review by US FDA - StreetInsider.com
06/09/16 07:01 AMIronwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review - [PR Newswire] - CAMBRIDGE, Mass. and DUBLIN, June 9, 2016 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. (IRWD) and Allergan plc (AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for the 72 mcg dose of linaclotide for use in the treatment of adults with chronic idiopathic constipation (CIC). The sNDA for the 72 mcg dose of linaclotide is based on efficacy and safety data from a double-blind, placebo-controlled Phase III clinical trial of 1,223 adult patients with CIC.

Social

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc. is a biotechnology company. The Company's products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IRWD
  • CUSIP: 46333X10
Key Metrics:
  • Previous Close: $14.27
  • 50 Day Moving Average: $13.03
  • 200 Day Moving Average: $11.05
  • P/E Ratio: N/A
  • P/E Growth: -0.63
  • Market Cap: $2.06B
  • Beta: 1.63
  • Current Year EPS Consensus Estimate: $-0.58 EPS
  • Next Year EPS Consensus Estimate: $-0.26 EPS
Additional Links:
Ironwood Pharmaceuticals (NASDAQ:IRWD) Chart for Monday, July, 25, 2016